BiotechTube
ten23 health

ten23 health

Basel, Switzerland· Est.
ten23.health
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $36.5M

Overview

Founded in 2021, ten23 health is an emerging, sustainability-focused CDMO providing end-to-end services for the development and sterile manufacturing of injectable therapeutics. It differentiates itself through a strong 'Patients, People, Planet' ethos, B Corp certification, and strategic investments in advanced capabilities like wearable injector integration and robot-assisted filling. The company has rapidly established key partnerships with major players like BD and biotechs like Neumirna Therapeutics, indicating strong market traction and a focus on next-generation drug delivery.

Drug DeliveryDigital Health

Technology Platform

Integrated CDMO services for sterile injectable drug products, specializing in formulation development, analytical testing, drug/device integration (e.g., wearable injectors), and aseptic fill & finish manufacturing, operated under a sustainability-focused (B Corp) model.

Funding History

2
Total raised:$36.5M
Series A$30M
Seed$6.5M

Opportunities

The booming market for biologics and RNA therapies, which require complex sterile manufacturing, presents a major growth opportunity.
Additionally, the industry trend towards patient-centric drug delivery, such as wearable injectors, aligns perfectly with ten23 health's expertise in drug/device integration, creating a specialized and high-value service niche.

Risk Factors

Key risks include operational and regulatory risks inherent in sterile manufacturing, where any contamination event or compliance issue could severely impact reputation.
The company also faces intense competition from larger, established CDMOs and relies on the success of its clients' therapeutic programs, introducing pipeline and concentration risk.

Competitive Landscape

ten23 health competes in the crowded global sterile injectables CDMO market against large players like Lonza, Catalent, and Recipharm, as well as other specialized Swiss CDMOs. Its differentiation is based on a strong sustainability (B Corp) brand, a focus on drug/device combination products, and agility as a newer, purpose-driven entrant serving both biotechs and pharma.

More companies in Switzerland →